{"id":10578,"date":"2020-08-18T18:31:43","date_gmt":"2020-08-18T13:01:43","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=10578"},"modified":"2021-07-24T12:58:03","modified_gmt":"2021-07-24T07:28:03","slug":"recent-pharma-happenings-for-sanofi-principia-roche-bms-dragonfly","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-principia-roche-bms-dragonfly","title":{"rendered":"Sanofi acquires Principia; FDA’s Nod to Roche’s Enspryng; BMS, Dragonfly’s Licensing Deal"},"content":{"rendered":"\n

New strategy, new outlook: Sanofi takes another step, gains full control over the Principia\u2019s MS treatment <\/strong><\/h2>\n\n\n\n
\"\"<\/figure>
\n

Sanofi has inked a definitive agreement with Principia Biopharma to acquire the company, all of its outstanding shares, and its BTK inhibitors in a deal worth USD 3.68 Billion. The deal is expected to complete in the fourth quarter of 2020.<\/p>\n<\/div><\/div>\n\n\n\n

The acquisition will help Sanofi transform its R & D and accelerate the discovery and manufacturing of novel medications in areas with significant unmet needs. <\/p>\n\n\n\n

\"\"<\/figure>
\n

Principia\u2019s experimental Bruton tyrosine kinase (BTK) inhibitors<\/a> will help Sanofi leverage the inhibitors\u2019 ability to block the signaling pathways of the immune system, thus preventing the inflammation and tissue damage due to autoimmune diseases. Sanofi had been in business-relation with Principia for a long time now.<\/p>\n<\/div><\/div>\n\n\n\n

Sanofi had earlier licensed-in Principia\u2019s experimental multiple sclerosis treatment ‘168; the late-stage pemphigus treatment Rilzabrutinib; and PRN473, a topical BTK inhibitor.<\/p>\n\n\n\n

Last year in December, the company had proposed to change its outlook to favor more lucrative areas, i.e., cancer research and abandon diabetes and cardiovascular research. The company had taken several steps, including the decision to spin off its API unit and divest in Regeneron to realize its goal. <\/p>\n\n\n\n

Make way for Roche: FDA\u2019s okay to Roche\u2019s NMOSD oral treatment Enspryng <\/strong><\/h2>\n\n\n\n
\"\"<\/figure>
\n

Roche has received the recommendations from the US FDA for its subcutaneous treatment Enspryng for the treatment of adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD)<\/a>. The drug is approved in Canada, Japan, and Switzerland for NMOSD. However, it is under review in the EU and China.<\/p>\n<\/div><\/div>\n\n\n\n

Administered orally, Enspryng is a humanized monoclonal antibody. The drug targets and inhibits interleukin-6 (IL-6) receptor believed to play a vital role in NMOSD-associated inflammation.<\/p>\n\n\n\n

Often misdiagnosed as multiple sclerosis, Neuromyelitis optica spectrum disorder (NMOSD) is a life-long, chronic disorder of the brain and spinal cord that inflammation the optic nerve (optic neuritis) and the spinal cord (myelitis), causing blindness, muscle weakness, and paralysis.<\/p>\n\n\n\n

USD 475 Million Deal: BMS Inks An A Global License Deal With Dragonfly For Immunotherapy Program <\/strong><\/h2>\n\n\n\n
\"\"<\/figure>
\n

Bristol Myers Squibb announced a definitive agreement with Dragonfly Therapeutics to gain global exclusive rights Dragonfly\u2019s interleukin-12 (IL-12) investigational immunotherapy program for treating solid and hematological cancers.<\/p>\n<\/div><\/div>\n\n\n\n

BMS is paying approximately USD 475 million to license Dragonfly Therapeutics\u2019 interleukin-12 (IL-12) immunotherapy program. This program is the early-stage experimental med DF6002, a monovalent IL-12 immunoglobulin Fc fusion protein. It functions by inducing an inflammatory tumor microenvironment to boost anti-tumor responses. The program includes DF6002, which is a monovalent IL-12 immunoglobulin Fc fusion protein.<\/p>\n\n\n\n

\"\"<\/figure>
\n

Recently, Dragonfly dosed its first patient in a Phase 1\/2 study of the Company’s proprietary IL12 investigational immunotherapy, DF6002. BMS now plans to advance the studies and research further exploring Dragonfly\u2019s immunotherapy program. <\/p>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"

New strategy, new outlook: Sanofi takes another step, gains full control over the Principia\u2019s MS treatment  Sanofi has inked a definitive agreement with Principia Biopharma to acquire the company, all of its outstanding shares, and its BTK inhibitors in a deal worth USD 3.68 Billion. The deal is expected to complete in the fourth quarter […]<\/p>\n","protected":false},"author":1,"featured_media":10587,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[130,18681,1771,18682,16874,16583,17661,524,533],"industry":[17225],"therapeutic_areas":[17227,17245,17234],"class_list":["post-10578","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-bristol-myers-squibb","tag-bruton-tyrosine-kinase-inhibitors","tag-cancers","tag-dragonfly","tag-neuromyelitis-optica-spectrum-disorder","tag-nmosd","tag-principia","tag-roche","tag-sanofi","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-neurology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"\nSanofi buys Principia; Roche's Enspryng Approval; BMS, Dragonfly's Deal<\/title>\n<meta name=\"description\" content=\"Sanofi acquires Principia; FDA's Nod to Roche's NMOSD Treatment Enspryng; BMS, Dragonfly's Licensing Deal For Immunotherapy Program\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-principia-roche-bms-dragonfly\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi buys Principia; Roche's Enspryng Approval; BMS, Dragonfly's Deal\" \/>\n<meta property=\"og:description\" content=\"Sanofi acquires Principia; FDA's Nod to Roche's NMOSD Treatment Enspryng; BMS, Dragonfly's Licensing Deal For Immunotherapy Program\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-principia-roche-bms-dragonfly\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-18T13:01:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/18183114\/New-strategy-new-outlook_-Sanofi-takes-another-step-gains-full-control-over-the-Principia%E2%80%99s-MS-treatment.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi buys Principia; Roche's Enspryng Approval; BMS, Dragonfly's Deal","description":"Sanofi acquires Principia; FDA's Nod to Roche's NMOSD Treatment Enspryng; BMS, Dragonfly's Licensing Deal For Immunotherapy Program","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-principia-roche-bms-dragonfly","og_locale":"en_US","og_type":"article","og_title":"Sanofi buys Principia; Roche's Enspryng Approval; BMS, Dragonfly's Deal","og_description":"Sanofi acquires Principia; FDA's Nod to Roche's NMOSD Treatment Enspryng; BMS, Dragonfly's Licensing Deal For Immunotherapy Program","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-principia-roche-bms-dragonfly","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-08-18T13:01:43+00:00","article_modified_time":"2021-07-24T07:28:03+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/18183114\/New-strategy-new-outlook_-Sanofi-takes-another-step-gains-full-control-over-the-Principia%E2%80%99s-MS-treatment.gif","type":"image\/gif"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-principia-roche-bms-dragonfly","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-principia-roche-bms-dragonfly","name":"Sanofi buys Principia; Roche's Enspryng Approval; BMS, Dragonfly's Deal","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-principia-roche-bms-dragonfly#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-principia-roche-bms-dragonfly#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/18183114\/New-strategy-new-outlook_-Sanofi-takes-another-step-gains-full-control-over-the-Principia%E2%80%99s-MS-treatment.gif","datePublished":"2020-08-18T13:01:43+00:00","dateModified":"2021-07-24T07:28:03+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Sanofi acquires Principia; FDA's Nod to Roche's NMOSD Treatment Enspryng; BMS, Dragonfly's Licensing Deal For Immunotherapy Program","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-principia-roche-bms-dragonfly"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-principia-roche-bms-dragonfly#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/18183114\/New-strategy-new-outlook_-Sanofi-takes-another-step-gains-full-control-over-the-Principia%E2%80%99s-MS-treatment.gif","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/18183114\/New-strategy-new-outlook_-Sanofi-takes-another-step-gains-full-control-over-the-Principia%E2%80%99s-MS-treatment.gif","width":772,"height":482,"caption":"pharma news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/18183114\/New-strategy-new-outlook_-Sanofi-takes-another-step-gains-full-control-over-the-Principia%E2%80%99s-MS-treatment-300x187.gif","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Bruton Tyrosine Kinase Inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">cancers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dragonfly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neuromyelitis optica spectrum disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">NMOSD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Principia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/span>","<span class=\"advgb-post-tax-term\">Bruton Tyrosine Kinase Inhibitors<\/span>","<span class=\"advgb-post-tax-term\">cancers<\/span>","<span class=\"advgb-post-tax-term\">Dragonfly<\/span>","<span class=\"advgb-post-tax-term\">Neuromyelitis optica spectrum disorder<\/span>","<span class=\"advgb-post-tax-term\">NMOSD<\/span>","<span class=\"advgb-post-tax-term\">Principia<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 18, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 18, 2020 6:31 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"pharma news ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=10578"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10578\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/10587"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=10578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=10578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=10578"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=10578"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=10578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}